Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. develops clinical-stage biopharmaceutical therapies for metabolic and endocrine disorders. News about VKTX centers on VK2735, a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral formulations for obesity and other metabolic disorders, including updates from the VANQUISH and VENTURE clinical programs.
Recurring company updates also cover financial results, corporate development, investor-conference participation, and earlier pipeline work such as an amylin agonist program. Viking's announcements typically connect clinical trial design, efficacy and safety data, regulatory interactions, and cash resources to the progress of its metabolic-disease portfolio.
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced its participation in two investor conferences from September 12-14, 2022. At the H.C. Wainwright 24th Annual Global Investment Conference, Dr. Lian will deliver a presentation on September 14 at 12:30 PM Eastern, with a hybrid format available. Additionally, Viking management will engage in 1-on-1 meetings at the Morgan Stanley 20th Annual Global Healthcare Conference during the same dates, held at the Sheraton New York Hotel. Webcasts of the presentations will be accessible via the Viking Therapeutics website.
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D., will participate in a fireside chat at the BTIG Biotechnology Conference 2022 on August 8-9, 2022. The event will be a hybrid format, facilitating both in-person and virtual attendance. Viking focuses on developing innovative therapies for metabolic and endocrine disorders, including its clinical programs VK2809, VK2735, and VK0214. VK2809 is currently in a Phase 2b study for non-alcoholic steatohepatitis, showing promising results for lipid and metabolic disorders.
Viking Therapeutics (NASDAQ: VKTX) reported Q2 2022 financial results, showing a net loss of $17.4 million, or $0.23 per share, compared to a loss of $15.4 million in Q2 2021. With $169 million in cash, the company is positioned to advance its clinical programs. Key updates include the VOYAGE Phase 2b study for VK2809, expected to complete enrollment in Q4 2022, and initial results from the Phase 1 study of VK2735 anticipated by year-end. Following FDA clearance, dosing for VK0214 in X-ALD patients is set to resume, with enrollment completion expected in H1 2023.
Viking Therapeutics (NASDAQ: VKTX) announced it will release its second quarter 2022 financial results on July 27, 2022, after market close. A conference call discussing these results and corporate updates is scheduled for 4:30 p.m. Eastern Time on the same day. Interested parties can join the call by dialing (844) 850-0543 from the U.S. or (412) 317-5199 internationally. For more details on the company's clinical programs, including VK2809 and VK2735, which target metabolic and endocrine disorders, visit www.vikingtherapeutics.com.
Viking Therapeutics (VKTX) announced the FDA has lifted the clinical hold on its Phase 1b trial for VK0214, aimed at treating X-linked adrenoleukodystrophy (X-ALD). The hold was lifted after an in vivo genotoxicity study showed no adverse effects. Enrollment for the trial will resume shortly. VK0214, a thyroid hormone beta receptor agonist, has achieved orphan drug designation and previously demonstrated encouraging safety and efficacy in earlier trials. The Phase 1b study targets patients with the AMN form of X-ALD, with primary objectives focused on safety and tolerability.
Viking Therapeutics, Inc. (NASDAQ: VKTX) will have CEO Brian Lian, Ph.D., participate in a fireside chat at the William Blair Biotech Focus Conference 2022 on July 12-13, 2022. The event will be held at The St. Regis, New York, with a webcast available starting July 11, 2022. Viking is focused on developing novel therapies for metabolic and endocrine disorders, with ongoing clinical programs including VK2809 for NASH and VK0214 for X-ALD. For more details, visit www.vikingtherapeutics.com.
Viking Therapeutics (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D., will present at the H.C. Wainwright Global Investment Conference from May 23-25, 2022. The presentation will be available online on May 24 at 7:00 a.m. Eastern. This hybrid conference includes both in-person and virtual participation. Viking's clinical programs focus on metabolic and endocrine disorders, with ongoing studies for VK2809, VK0214, and VK2735. VK2809 is currently in a Phase 2b trial for NASH and fibrosis, following successful Phase 2a results for NAFLD.
Viking Therapeutics (VKTX) reported its Q1 2022 financial results, showing a net loss of $16.1 million ($0.21 per share), up from $14 million ($0.19 per share) year-over-year. The company highlighted the ongoing Phase 2b VOYAGE study for VK2809 in NASH, with enrollment completion expected in 2H22. Additionally, the Phase 1 trial of VK2735 is ongoing, with results anticipated by year-end. With a cash balance of $185 million, Viking maintains a strong financial position to support its clinical programs through key upcoming data readouts.
Viking Therapeutics (NASDAQ: VKTX) will release its Q1 2022 financial results on April 27, 2022, post-market. A conference call is scheduled for 4:30 PM ET the same day to discuss the results and corporate updates. Key clinical programs include VK2809, a treatment for NASH, and VK0214, investigating X-ALD. The company aims to leverage its expertise in metabolic therapies to enhance patient outcomes.
Viking Therapeutics (NASDAQ: VKTX) announced that CEO Brian Lian will present at the 21st Annual Needham Virtual Healthcare Conference from April 11-14, 2022. Lian's presentation is scheduled for April 13, 2022, from 11:15 to 11:55 a.m. Pacific. Attendees can access a live webcast through the Viking Therapeutics website, which will also host a replay post-conference. Viking focuses on innovative therapies for metabolic and endocrine disorders, with ongoing clinical programs for its candidates VK2809, VK0214, and VK2735.